Blueprint Medicines Takes $40MM From Third Rock To Build Oncology Platform
This article was originally published in The Pink Sheet Daily
Incubated for months within TRV, the Boston-area startup aims to discover highly specific cancer drugs for personalized medicine.
You may also be interested in...
Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
In the firm’s largest solo investment ever, Third Rock backed a new platform company that will seek to identify and develop a pipeline of drugs for rare blood disorders.
The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.